Overview of the Therapeutic Management of Insomnia with Zolpidem

@article{Lee2004OverviewOT,
  title={Overview of the Therapeutic Management of Insomnia with Zolpidem},
  author={Yue Joe Lee},
  journal={CNS Drugs},
  year={2004},
  volume={18},
  pages={17-23}
}
  • Y. Lee
  • Published 1 November 2004
  • Psychology, Medicine
  • CNS Drugs
Benzodiazepine hypnotic agents were the mainstream pharmacotherapy for insomnia from the 1960s to the 1980s, but their safety profile proved to be not quite as perfect as originally expected with regard to daytime performance and cognition, and above all the risk of dependence. These risks are substantially diminished in the non-benzodiazepine hypnotic agents developed and marketed during the past two decades, but the fears engendered by certain benzodiazepines still greatly influence the… 
Pharmacologic Treatments of Insomnia
  • M. Chu
  • Medicine, Psychology
  • 2006
Characterized by disorders of initiating or maintaining sleep, or nonrestorative sleep, insomnia is a prevalent condition that can coexist with psychiatric and medical illness and cause significant
Therapeutic Options for Sleep‐Maintenance and Sleep‐Onset Insomnia
TLDR
Clinicians should consider patient‐specific criteria such as age, medical history, and other drug use, as well as the underlying cause of the sleep disturbance, before recommending any treatment.
Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: A randomized controlled trial
TLDR
NSF-3 is a safe and effective short-term alternative to zolpidem for primary insomnia and it remains to be explored whether the benefits are sustained and whether there is dependence liability with this formulation upon long term use.
Postural Instability and Consequent Falls and Hip Fractures Associated with Use of Hypnotics in the Elderly
TLDR
Data obtained in laboratory settings, where confounding factors can be eliminated, prove that benzodiazepine-1 (BZ1) receptors are the most deleterious hypnotics at least in terms of their effects on body sway.
Current awareness in human psychopharmacology
TLDR
The bibliography contains newly published material in the field of human psychopharmacology that is relevant to any one of these headings, and if, in the preceding period, no publications are located relevant to this section, that section will be omitted.
Pharmacotherapy of Insomnia: Focus on Zolpidem Extended Release
The imidazopyridine drug zolpidem (N,N,6-trimethyl-2[4-methyl-phenyl]imidazo[1,2-a]pyridine-3-acetamide) is a sedative/hypnotic with relative selectivity for α1 subunits of the GABAA receptor/chlor...
Zolpidem Use and Risk of Fracture in Elderly Insomnia Patients
TLDR
Zolpidem could increase the risk of fracture in elderly insomnia patients and should be prescribed carefully and the elderly should be provided with sufficient patient education.
항암화학요법을 받는 대장암 입원 환자들의 수면장애 및 관련요인: 후향적 조사
TLDR
Sleep disturbances were influenced by body mass index, targeted therapy, and length of hospital stay, and nutritional and psycho-emotional status after metastasis or recurrence should be closely monitored in patients with colorectal cancer undergoing chemotherapy.
Detailed quantum mechanical studies on bioactive benzodiazepine derivatives and their adsorption over graphene sheets.
  • J. S. Al-Otaibi
  • Chemistry
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  • 2020

References

SHOWING 1-10 OF 25 REFERENCES
Consensus for the pharmacological management of insomnia in the new millennium.
TLDR
This report from the XXII Collegium Internationale Neuro-Psychopharmacologicum Consensus Workshop outlines recommendations to serve as the foundation for developing a therapeutic plan for each patient.
A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
TLDR
10 mg of zolpidem was found to be safe and effective for the long-term treatment of chronic insomnia, demonstrating hypnotic efficacy without affecting sleep stages or producing tolerance effects, rebound effects, or detrimental effects on psychomotor performance.
Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.
TLDR
Although zolpidem produced some psychomotor and memory impairment over the first few hours after administration, it had few next-day effects and was comparable or superior to flunitrazepam and flurazep am and comparable to other benzodiazepines in patients with insomnia.
Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.
TLDR
While zolpidem aids sedation, and may reduce memory or psychomotor function within the first 2 hours after administration of single oral doses, its use as a surgical premedicant remains to be established.
The Safety and Efficacy of Zolpidem in Insomniac Patients: A Long-Term Open Study in General Practice
TLDR
Zolpidem has been shown to be an effective and safe hypnotic, and to be devoid of rebound and withdrawal effects.
Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies.
TLDR
There are differences among the rapidly eliminated hypnotics with respect to tolerance and rebound insomnia suggesting that, in addition to short elimination half-life, other pharmacological properties are implicated in the mechanisms underlying these side-effects.
Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem
TLDR
Zolpidem is a strong sedative with only minor anxiolytic, myorelaxant and anticonvulsant properties, and has been shown to be effective in inducing and maintaining sleep in adults.
Nonpharmacologic Treatment of Chronic Insomnia
TLDR
The findings indicate that nonpharmacological therapies produce reliable and durable changes in several sleep parameters of chronic insomnia sufferers and there is no clear evidence that improved sleep leads to meaningful changes in daytime well-being or performance.
Minimal rebound insomnia after treatment with 10-mg zolpidem.
TLDR
There was no significant correlation between rebound insomnia and the level of initial insomnia, the degree of response to treatment in week 4, or the amount of tolerance that developed during drug use.
...
1
2
3
...